investors

Press Releases
Date Title and Summary View
April 12, 2018 LOS ANGELES, April 12, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells. This milestone represents the next important step in validatin...
March 26, 2018 LOS ANGELES, March 26, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 14, 2018, the audited financial statements contained an...
March 13, 2018 LOS ANGELES, March 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the fourth quarter and full year ended December 31, 2017.   Anthony J. Gringeri, PhD, President and Chief Executive Officer commented: "We end...
March 7, 2018 LOS ANGELES, March 7, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that it plans to report fourth quarter and full year 2017 financial results on Tuesday, March 13, 2018. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the 2017 finan...
February 22, 2018 LOS ANGELES, Feb. 22, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has retained Ladenburg Thalmann & Co. Inc. as its strategic financial advisor to a...
February 13, 2018 LOS ANGELES, Feb. 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that during the fourth quarter ended December 31, 2017, the Company received approximately...
December 13, 2017 LOS ANGELES, Dec. 13, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The milestone represents an important step toward stimulating the patient's immune system to produce a...
November 22, 2017 LOS ANGELES, Nov. 22, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Senior Vic...
November 21, 2017 LOS ANGELES, Nov. 21, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the third quarter 2017.   Anthony J. Gringeri, PhD, President and Chief Executive Officer commented: "As a result of the July financing and str...
November 17, 2017 LOS ANGELES, Nov. 17, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results on Tuesday, November 21, 2017. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2017 financia...
1
... NextLast
Add to Briefcase = add release to Briefcase
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved